These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33467978)

  • 1. Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care.
    Jalusic KO; Ellenberger D; Rommer P; Stahmann A; Zettl U; Berger K
    Mult Scler; 2021 Oct; 27(12):1852-1863. PubMed ID: 33467978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events in MS patients fulfilling or not inclusion criteria of the respective clinical trial - The problem of generalizability.
    Jalusic KO; Ellenberger D; Stahmann A; Berger K;
    Mult Scler Relat Disord; 2023 Jan; 69():104422. PubMed ID: 36455503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
    Foo EC; Russell M; Lily O; Ford HL
    Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitoxantrone for multiple sclerosis.
    Martinelli Boneschi F; Vacchi L; Rovaris M; Capra R; Comi G
    Cochrane Database Syst Rev; 2013 May; (5):CD002127. PubMed ID: 23728638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol.
    Dirks P; Zingler V; Leemhuis J; Berthold H; Hieke-Schulz S; Wormser D; Ziemssen T
    BMC Neurol; 2020 Mar; 20(1):95. PubMed ID: 32171264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany.
    Rauer S; Hoshi MM; Pul R; Wahl M; Schwab M; Haas J; Ellrichmann G; Krumbholz M; Tackenberg B; Saum KU; Buck F; Leemhuis J; Kretschmann A; Aktas O
    Clin Neurol Neurosurg; 2020 Oct; 197():106142. PubMed ID: 32920498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocrelizumab for the treatment of multiple sclerosis.
    Bigaut K; De Seze J; Collongues N
    Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis.
    Stühler E; Braune S; Lionetto F; Heer Y; Jules E; Westermann C; Bergmann A; van Hövell P;
    BMC Med Res Methodol; 2020 Feb; 20(1):24. PubMed ID: 32028898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population.
    Coban H; Germaine S; Dimaandal I; Haberli N; Padam C; Creed MA; Imitola J
    Mult Scler Relat Disord; 2021 Aug; 53():103021. PubMed ID: 34077828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?
    Brancati S; Gozzo L; Longo L; Vitale DC; Drago F
    Front Immunol; 2021; 12():661882. PubMed ID: 34295328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
    Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
    Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laquinimod for multiple sclerosis.
    He D; Han K; Gao X; Dong S; Chu L; Feng Z; Wu S
    Cochrane Database Syst Rev; 2013 Aug; (8):CD010475. PubMed ID: 23922214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history.
    Sorensen PS; Sellebjerg F; Hartung HP; Montalban X; Comi G; Tintoré M
    Brain; 2020 Sep; 143(9):2637-2652. PubMed ID: 32710096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.